Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center
Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteris...
Gespeichert in:
| Veröffentlicht in: | Journal of dermatology 2021-07, Vol.48 (7), p.979-988 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 988 |
|---|---|
| container_issue | 7 |
| container_start_page | 979 |
| container_title | Journal of dermatology |
| container_volume | 48 |
| creator | Park, Ji‐Hye Yoon, Dokyoung Lee, Jeeyun Oh, Se Jin Kim, Hyun Je Lee, Jong Hee Lee, Dong‐Youn |
| description | Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteristics of CAE in patients treated with PD‐1/PD‐L1 inhibitors through the medical records, photographs, and pathology reports. Fifty CAE occurred in 47 (2.75%) of 1711 patients treated with PD‐1/PD‐L1 inhibitors. Pruritic, psoriasiform, urticarial, and acneiform eruptions were the four most common types. Melanoma patients showed CAE more frequently than other malignancies. Acneiform eruption occurred more often at ages under 60 years. Urticarial eruption appeared earlier, while keratoacanthoma appeared later after immunotherapy. The overall survival times were not significantly different between the two groups with and without CAE by Kaplan–Meier analysis (p = 0.055). Studies on CAE may provide more information to understand these drugs and to help manage the patients. |
| doi_str_mv | 10.1111/1346-8138.15824 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2516226222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2546821517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3954-732ac5d7e380e81cbd4d4ded0c58311f8da1246bc3aa2b678504de52e5972c4f3</originalsourceid><addsrcrecordid>eNqFkbtPwzAQxi0EgvKY2ZAlFpaAH3Hijqi8hcQCs-U4F-qSR7GTIv57rgQ6sGBbOsv3u0--7wg55uyc47rgMs0SzaU-50qLdItMNi_bZMKkVolIWb5H9mNcMCamirNdsielzrXg0wmZz2rfemdrugxd5WugXUXd0NsWuiFSW64gRKCwgraP65xvmqEF6ubg3padb3vq27kvfN-FiFdqafTtK-r0EHpvwyd1WArhkOxUto5w9BMPyMvN9fPsLnl8ur2fXT4mTk5VmuRSWKfKHKRmoLkryhQ3lMwpLTmvdGm5SLPCSWtFkeVaMUwrAWqaC5dW8oCcjbrYz_sAsTeNjw7qeuzICMUzIfAIRE__oItuCC3-Dqk0Q4MUz5G6GCkXuhgDVGYZfIONGc7MeghmbblZW26-h4AVJz-6Q9FAueF_XUdAjcAHGv75n555uLoehb8AkUmRkQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546821517</pqid></control><display><type>article</type><title>Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center</title><source>Access via Wiley Online Library</source><creator>Park, Ji‐Hye ; Yoon, Dokyoung ; Lee, Jeeyun ; Oh, Se Jin ; Kim, Hyun Je ; Lee, Jong Hee ; Lee, Dong‐Youn</creator><creatorcontrib>Park, Ji‐Hye ; Yoon, Dokyoung ; Lee, Jeeyun ; Oh, Se Jin ; Kim, Hyun Je ; Lee, Jong Hee ; Lee, Dong‐Youn</creatorcontrib><description>Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteristics of CAE in patients treated with PD‐1/PD‐L1 inhibitors through the medical records, photographs, and pathology reports. Fifty CAE occurred in 47 (2.75%) of 1711 patients treated with PD‐1/PD‐L1 inhibitors. Pruritic, psoriasiform, urticarial, and acneiform eruptions were the four most common types. Melanoma patients showed CAE more frequently than other malignancies. Acneiform eruption occurred more often at ages under 60 years. Urticarial eruption appeared earlier, while keratoacanthoma appeared later after immunotherapy. The overall survival times were not significantly different between the two groups with and without CAE by Kaplan–Meier analysis (p = 0.055). Studies on CAE may provide more information to understand these drugs and to help manage the patients.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.15824</identifier><identifier>PMID: 33878219</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acne ; Adverse events ; atezolizumab ; Cancer therapies ; Dermatology ; drug eruption ; Immune checkpoint ; Immunomodulation ; Immunosuppressive agents ; Immunotherapy ; Medical records ; Melanoma ; Monoclonal antibodies ; nivolumab ; Patients ; PD-1 protein ; PD-L1 protein ; pembrolizumab ; programmed death 1/programmed death ligand 1 ; Pruritus ; Psoriasis ; Side effects ; Skin eruptions ; Targeted cancer therapy ; Urticaria</subject><ispartof>Journal of dermatology, 2021-07, Vol.48 (7), p.979-988</ispartof><rights>2021 Japanese Dermatological Association</rights><rights>2021 Japanese Dermatological Association.</rights><rights>Copyright © 2021 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3954-732ac5d7e380e81cbd4d4ded0c58311f8da1246bc3aa2b678504de52e5972c4f3</citedby><cites>FETCH-LOGICAL-c3954-732ac5d7e380e81cbd4d4ded0c58311f8da1246bc3aa2b678504de52e5972c4f3</cites><orcidid>0000-0002-4184-6702 ; 0000-0002-6699-5202 ; 0000-0001-7525-4740 ; 0000-0003-0765-9812 ; 0000-0002-1769-4921 ; 0000-0001-8536-1179</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1346-8138.15824$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1346-8138.15824$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33878219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Ji‐Hye</creatorcontrib><creatorcontrib>Yoon, Dokyoung</creatorcontrib><creatorcontrib>Lee, Jeeyun</creatorcontrib><creatorcontrib>Oh, Se Jin</creatorcontrib><creatorcontrib>Kim, Hyun Je</creatorcontrib><creatorcontrib>Lee, Jong Hee</creatorcontrib><creatorcontrib>Lee, Dong‐Youn</creatorcontrib><title>Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteristics of CAE in patients treated with PD‐1/PD‐L1 inhibitors through the medical records, photographs, and pathology reports. Fifty CAE occurred in 47 (2.75%) of 1711 patients treated with PD‐1/PD‐L1 inhibitors. Pruritic, psoriasiform, urticarial, and acneiform eruptions were the four most common types. Melanoma patients showed CAE more frequently than other malignancies. Acneiform eruption occurred more often at ages under 60 years. Urticarial eruption appeared earlier, while keratoacanthoma appeared later after immunotherapy. The overall survival times were not significantly different between the two groups with and without CAE by Kaplan–Meier analysis (p = 0.055). Studies on CAE may provide more information to understand these drugs and to help manage the patients.</description><subject>Acne</subject><subject>Adverse events</subject><subject>atezolizumab</subject><subject>Cancer therapies</subject><subject>Dermatology</subject><subject>drug eruption</subject><subject>Immune checkpoint</subject><subject>Immunomodulation</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Medical records</subject><subject>Melanoma</subject><subject>Monoclonal antibodies</subject><subject>nivolumab</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>pembrolizumab</subject><subject>programmed death 1/programmed death ligand 1</subject><subject>Pruritus</subject><subject>Psoriasis</subject><subject>Side effects</subject><subject>Skin eruptions</subject><subject>Targeted cancer therapy</subject><subject>Urticaria</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkbtPwzAQxi0EgvKY2ZAlFpaAH3Hijqi8hcQCs-U4F-qSR7GTIv57rgQ6sGBbOsv3u0--7wg55uyc47rgMs0SzaU-50qLdItMNi_bZMKkVolIWb5H9mNcMCamirNdsielzrXg0wmZz2rfemdrugxd5WugXUXd0NsWuiFSW64gRKCwgraP65xvmqEF6ubg3padb3vq27kvfN-FiFdqafTtK-r0EHpvwyd1WArhkOxUto5w9BMPyMvN9fPsLnl8ur2fXT4mTk5VmuRSWKfKHKRmoLkryhQ3lMwpLTmvdGm5SLPCSWtFkeVaMUwrAWqaC5dW8oCcjbrYz_sAsTeNjw7qeuzICMUzIfAIRE__oItuCC3-Dqk0Q4MUz5G6GCkXuhgDVGYZfIONGc7MeghmbblZW26-h4AVJz-6Q9FAueF_XUdAjcAHGv75n555uLoehb8AkUmRkQ</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Park, Ji‐Hye</creator><creator>Yoon, Dokyoung</creator><creator>Lee, Jeeyun</creator><creator>Oh, Se Jin</creator><creator>Kim, Hyun Je</creator><creator>Lee, Jong Hee</creator><creator>Lee, Dong‐Youn</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4184-6702</orcidid><orcidid>https://orcid.org/0000-0002-6699-5202</orcidid><orcidid>https://orcid.org/0000-0001-7525-4740</orcidid><orcidid>https://orcid.org/0000-0003-0765-9812</orcidid><orcidid>https://orcid.org/0000-0002-1769-4921</orcidid><orcidid>https://orcid.org/0000-0001-8536-1179</orcidid></search><sort><creationdate>202107</creationdate><title>Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center</title><author>Park, Ji‐Hye ; Yoon, Dokyoung ; Lee, Jeeyun ; Oh, Se Jin ; Kim, Hyun Je ; Lee, Jong Hee ; Lee, Dong‐Youn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3954-732ac5d7e380e81cbd4d4ded0c58311f8da1246bc3aa2b678504de52e5972c4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acne</topic><topic>Adverse events</topic><topic>atezolizumab</topic><topic>Cancer therapies</topic><topic>Dermatology</topic><topic>drug eruption</topic><topic>Immune checkpoint</topic><topic>Immunomodulation</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Medical records</topic><topic>Melanoma</topic><topic>Monoclonal antibodies</topic><topic>nivolumab</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>pembrolizumab</topic><topic>programmed death 1/programmed death ligand 1</topic><topic>Pruritus</topic><topic>Psoriasis</topic><topic>Side effects</topic><topic>Skin eruptions</topic><topic>Targeted cancer therapy</topic><topic>Urticaria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Ji‐Hye</creatorcontrib><creatorcontrib>Yoon, Dokyoung</creatorcontrib><creatorcontrib>Lee, Jeeyun</creatorcontrib><creatorcontrib>Oh, Se Jin</creatorcontrib><creatorcontrib>Kim, Hyun Je</creatorcontrib><creatorcontrib>Lee, Jong Hee</creatorcontrib><creatorcontrib>Lee, Dong‐Youn</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Ji‐Hye</au><au>Yoon, Dokyoung</au><au>Lee, Jeeyun</au><au>Oh, Se Jin</au><au>Kim, Hyun Je</au><au>Lee, Jong Hee</au><au>Lee, Dong‐Youn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2021-07</date><risdate>2021</risdate><volume>48</volume><issue>7</issue><spage>979</spage><epage>988</epage><pages>979-988</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteristics of CAE in patients treated with PD‐1/PD‐L1 inhibitors through the medical records, photographs, and pathology reports. Fifty CAE occurred in 47 (2.75%) of 1711 patients treated with PD‐1/PD‐L1 inhibitors. Pruritic, psoriasiform, urticarial, and acneiform eruptions were the four most common types. Melanoma patients showed CAE more frequently than other malignancies. Acneiform eruption occurred more often at ages under 60 years. Urticarial eruption appeared earlier, while keratoacanthoma appeared later after immunotherapy. The overall survival times were not significantly different between the two groups with and without CAE by Kaplan–Meier analysis (p = 0.055). Studies on CAE may provide more information to understand these drugs and to help manage the patients.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33878219</pmid><doi>10.1111/1346-8138.15824</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4184-6702</orcidid><orcidid>https://orcid.org/0000-0002-6699-5202</orcidid><orcidid>https://orcid.org/0000-0001-7525-4740</orcidid><orcidid>https://orcid.org/0000-0003-0765-9812</orcidid><orcidid>https://orcid.org/0000-0002-1769-4921</orcidid><orcidid>https://orcid.org/0000-0001-8536-1179</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0385-2407 |
| ispartof | Journal of dermatology, 2021-07, Vol.48 (7), p.979-988 |
| issn | 0385-2407 1346-8138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2516226222 |
| source | Access via Wiley Online Library |
| subjects | Acne Adverse events atezolizumab Cancer therapies Dermatology drug eruption Immune checkpoint Immunomodulation Immunosuppressive agents Immunotherapy Medical records Melanoma Monoclonal antibodies nivolumab Patients PD-1 protein PD-L1 protein pembrolizumab programmed death 1/programmed death ligand 1 Pruritus Psoriasis Side effects Skin eruptions Targeted cancer therapy Urticaria |
| title | Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T21%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20profile%20of%20cutaneous%20adverse%20events%20of%20immune%20checkpoint%20inhibitors%20in%20a%20single%20tertiary%20center&rft.jtitle=Journal%20of%20dermatology&rft.au=Park,%20Ji%E2%80%90Hye&rft.date=2021-07&rft.volume=48&rft.issue=7&rft.spage=979&rft.epage=988&rft.pages=979-988&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.15824&rft_dat=%3Cproquest_cross%3E2546821517%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546821517&rft_id=info:pmid/33878219&rfr_iscdi=true |